Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes

Hormone and Metabolic Research

Volumn 32, Issue 10, 2000, Pages 424-428

  Lugari, R ^a   Dell'Anna, C ^a   Ugolotti, D ^a   Dei Cas, A ^a   Barilli, A L ^a   Zandomeneghi, R ^b   Marani, B ^b   Iotti, M ^b   Orlandini, A ^b   Gnudi, A ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Diabetes; Entero Insular Axis; GLP 1

Indexed keywords

C PEPTIDE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DIET RESTRICTION; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRIENT; PRIORITY JOURNAL; PROTEIN DETERMINATION;

EID: 0033765237     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-978665     Document Type: Article

References (28)

1. Glucagon-like peptide 1 (7-36): A physiological incretin in man
2. Addictive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptice and glucagon-like peptide 1 (7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations
3. The enteroinsular axis revised: A novel role for an incretin
4. Insuliotropic glucagon-like peptide 1 (7-37)/(7-36) amide. A new incretin hormone
5. Exendin (9-39) amide is an antagonist of glucagon-like peptide 1 (7-36) amide in humans
6. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans. Studies with the antagonist exendin 9-39
7. Antidiabetogenic effect of glucagon-like peptide 1 (7-36 amide) in normal subjects and in patients with diabetes mellitus
8. Truncated GLP-1 (proglucagon 78-107 amide) inhibits gastric and pancreatic functions in man
9. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
10. Ileal release of glucagon-like peptide 1 (GLP-1). Association with inhibition of gastric acid secretion in humans
11. Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus
12. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non insulin-dependent) diabetic patients
13. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide 1 (GLP-1) (7-36 amide) in type 2 (non insulin-dependent) diabetic patients
14. Glucagon-like peptide 1: A potent gut hormone with a possible therapeutic perspective
15. Glucagonostatic actions and reduction of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36) amide in type 1 diabetic patients
16. Glucagon-like peptide 1 reduces postprandial glycaemic excursions in IDDM
17. Reduced incretin effect in type 2 (non insulin-dependent) diabetes
18. Absence of incretin effect in obese type 2 and diminished effect in lean type 2 and obese subjects
19. Proglucagon products in plasma of non insulin-dependent diabetics and non diabetic controls in the fasting state and following oral glucose and intravenous arginine
20. Glycation of glucagon-like peptide 1 (7-36) amide: Characterization and impaired action on rat insulin secreting cells
21. Both subcutaneously and intravenously glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2 diabetic patients and in healthy subjects
22. Is glucagon-like peptide 1 an incretin hormone?
23. In vitro insulinomimetic effects of GLP-1 in liver, muscle and fat
24. The effect of glucagon-like peptide (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones
25. GLP-1 does not acutely affect insulin sensitivity in healthy man
26. Subcutaneous glucagon-like peptide 1 combined with insulin normalizes postcibal glycaemic excursions in IDDM
27. Role of hyperglucagonaemia in maintenance of increased rates of hepatic glucose output in type 2 diabetics
28. Glucagon and the A-cell. Physiology and pathophysiology